Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01496755 · ClinicalTrials.gov registry record · Phase 1
A Study of RG7667 in Healthy Volunteers
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 170
- Enrollment target
NCT01496755 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 170 participants.
The verdict
NCT01496755, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 170 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled study will evaluate the safety and pharmacokinetics of RG7667 in healthy volunteers. Subjects will be randomized in cohorts to receive either single/multiple doses of RG7667 intravenously or placebo. Anticipated time on study treatment is up to 57 days with a 12-week follow-up.
Interventions
- DRUG Placebo
- DRUG RG7667
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01496755
The ClinicalTrials.gov registry entry for NCT01496755 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01496755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01496755 about?
NCT01496755 is a clinical study titled "A Study of RG7667 in Healthy Volunteers". This randomized, double-blind, placebo-controlled study will evaluate the safety and pharmacokinetics of RG7667 in healthy volunteers. Subjects will be randomized in cohorts to receive either single/multiple doses of RG7667 intravenously or placebo. Anticipated time on study treatment is up to 57 da...
What is the current status of trial NCT01496755?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 170 participants. The study started on 2012-01. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01496755?
The interventions under investigation include: Placebo (DRUG), RG7667 (DRUG).
Who is sponsoring clinical trial NCT01496755?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.